10 Firms Fall Amid Disappointing Earnings Performance

3. Merck & Co. Inc. (NYSE:MRK)

Pharmaceutical giant Merck & Co. saw its share prices decrease by 9.07 percent on Tuesday to end at $90.74 apiece after providing a lower 2025 outlook guidance.

The company set a sales guidance between $64.1 billion and $65.6 billion in full-year 2025, or lower than the Wall Street consensus of $67.4 billion.

Likewise, its targeted earnings per share were lower at $8.88 to $9.03, as compared with analysts’ expectations of $9.21.

In the fourth quarter of 2024, Merck delivered a net income of $3.74 billion, which, albeit marking a swing from a net loss of $1.2 billion in the same quarter in 2023, was noticeably lower than Wall Street’s estimate of $3.92 billion.

For the full year, Merck reported $64.2 billion in revenues, representing a 7 percent increase from 2023.